Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients. - Suzuki K; Gunji T; Nagao R; Kawashima M; Uryu H; Momoki M; Ishii H; Fukushima R; Katori M; Yokoyama H; Katsube A; Saito T; et al. (International journal of hematology, 2025)